Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruixuan Luo

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Neural Networks : the Official Journal of the International Neural Network Society|September 9, 2021
Adversarial parameter defense by multi-step risk minimizationZhiyuan Zhang, Ruixuan Luo, Xuancheng Ren, et al.
Drug Design, Development and Therapy|March 24, 2026
Safety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy SubjectsXiaojia Yang, Min Xu, Nan Cao, et al.
Eclinicalmedicine|June 16, 2025
Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II studyPanpan Zhang, Kai Chen, Jianwei Yang, et al.
Journal for Immunotherapy of Cancer|October 4, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I studyNingning Zhang, Tian Liu, Ming Luo, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Neural Networks : the Official Journal of the International Neural Network Society|September 9, 2021
Adversarial parameter defense by multi-step risk minimizationZhiyuan Zhang, Ruixuan Luo, Xuancheng Ren, et al.
Drug Design, Development and Therapy|March 24, 2026
Safety, Tolerability, and Pharmacokinetics of HBM9378 (SKB378/WIN378), a Fully Human IgG1 Monoclonal Antibody Against TSLP After Single Ascending Doses in Chinese Healthy SubjectsXiaojia Yang, Min Xu, Nan Cao, et al.
Eclinicalmedicine|June 16, 2025
Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II studyPanpan Zhang, Kai Chen, Jianwei Yang, et al.
Journal for Immunotherapy of Cancer|October 4, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I studyNingning Zhang, Tian Liu, Ming Luo, et al.
Pageof 1